Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: Roger Mathias who wrote (1164)	1/27/1998 7:47:00 AM
From: EZLibra	Respond to of 3702

The company said both trials, the P I and the P III, would begin in the first calendar quarter. I also think it would be more than prudent to have some sort of explanation out of Tustin, of anything. By the way, I think the TNT trial is much more important than the Lym-1 trial. Analysts' estimates of revenue from nonHodgkins lymphoma are wildly speculative. Success in the glioma trial will be looked upon as a validation for treating all solid tumors, and don't forget the trailing trial for pediatric glioma that the government will sponsor.

To: Roger Mathias who wrote (1164)	1/27/1998 9:24:00 AM
From: shero	Respond to of 3702

Trails have not started. FDA gave approval after the shareholders meeting , end of Oct. Then TCLN bought back the rights from Alpha. Then TCLN submitted a new protocol and we are waiting to hear. I won't even go into the logic that went into buying back LYM-1 and taking on more expenses as the company was running out of money. We know managers are supposed to be able to forecast expenses and figure out how long the money lasts. But not these guys. And I'm afraid to see what they will do for an encore.